Find a Provider

Ravi K. Amaravadi, MD

Ravi K. Amaravadi, MD Physician

Associate Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Amaravadi is a Penn Medicine employed physician.

Clinical Specialties


  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Bladder Cancer
    • Early Phase Clinical Trials - Developmental Therapeutics
    • Kidney Cancer
    • Merkel Cell Carcinoma
    • Penile Cancer
    • Prostate Cancer
    • Skin Cancer
    • Testicular Cancer
    • Urethral Cancer

Board Certification:

  • Medical Oncology, 2006

Conditions & Treatments:

  • Bladder Cancer
  • Cancer Clinical Trials
  • Kidney Cancer
  • melanoma
  • Melanoma
  • Melanoma
  • Non-Melanoma Skin Cancer
  • Penile Cancer
  • phase 1 clinical trials
  • Prostate Cancer
  • Skin Cancer
  • Testicular Cancer
  • Urethral Cancer

Clinical Interests

Phase I and Phase II Clinical Trials

Practice Locations and Appointments

  • Genito-urinary Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

  • Melanoma and Pigmented Lesions

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Johns Hopkins University School of Medicine
Residency: Brigham and Women's Hospital
Fellowship: Hospital of the University of Pennsylvania


American Association for Cancer Research, National American Association for the Advancement of Science, National American Society of Clinical Oncology, National Austrian Science Fund (FWF),, International Beyond Batten Disease Foundation, International Health Research Ireland, International Melanoma Research Foundation Breakthrough Consortium, National Melanoma Research Foundation, National NCI -J special emphasis panel study section for K awards, National NIH Loan repayment program, National Presage Biosciences, National Sprint Biosciences, International Wistar Institute, Cancer Center, Tumor Microenvironment and Metastases Program, Local


Dr. Amaravadi is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Research Interests:

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Selected Publications:

Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odiorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma D, Xu X, Feldman M, Gangadhar T, Hahn S, Wherry JE, Vonderheide R, Benci J, Minn A.: Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer Nature : 2015.

Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA.: A Phase 1 Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics : 2015.

Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR.: Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research : 2015.

Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ.: Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. The Oncologist : 2015.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis GC, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res. : 2015.

Krayya A, Piao S, Xu G, Zhang G, Gimotty PG, Xu X, Amaravadi RK**, Speicher DW**. **Co-senior authors.: Identification of secreted proteins that reflect autophagy dynamics with tumor cells Autophagy 11 (1): 60-74,2015.

Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB.: Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer 51 (11): 1435-43,2015.

Kong J, Whelan KA, Laczkó D, Dang B, Caro Monroig A, Soroush A, Falcone J, Amaravadi RK, Rustgi AK, Ginsberg GG, Falk GW, Nakagawa H, Lynch JP.: Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. . PMID: 26373456 Molecular Carcinogenesis doi: 10.1002/mc.22406. : 2015.

Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, Herlyn M, Yao Y, Zhang L, Wang Y, Zhang L, Xu X.: miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell and Melanoma Research 28 (4): 431-41,2015.

Hubbard-Lucey V, Shono Y,Maurer K,West ML,Singer NV, Ziegler CG, Lezcano, C, Motta AC,Schmid K,Levi SM,Murphy GF,Liu C,Winkler JD,Amaravadi JK,Rogler G,Dickinson AM,Holler E,van den Brink M,Cadwell K: Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells Immunity :,2014.

Academic Contact Info

Hematology-Oncology Division
University of Pennsylvania
16 Penn Tower
3400 Spruce St.

Philadelphia, PA 19104
Phone: (215) 662-7402
Fax: (215) 349-8550
Patient appointments: 800-789-PENN (7366)

Related Links